Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dezocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 13/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dezocine SCHEMBL29811203 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL29682715 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL12720257 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL9685743 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL11874182 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL3072 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL7781933 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL11874190 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL1369581 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL25583319 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| US-11534436-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-27 | — | — | US | disclosed |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-01-07 | — | — | US | disclosed |
| US-10736890-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-11 | — | — | US | disclosed |
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885 |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885 |
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885 |
| US-11534436-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885 |
| US-10736890-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.